ALDEYRA THERAPEUTICS, INC. Financing Cash Flow
ALDEYRA THERAPEUTICS, INC. (ALDX) reported Financing Cash Flow of -$15.23 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-06
- ALDEYRA THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was -$15.30M.
- ALDEYRA THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $71.14K, a 92.91% decline year-over-year.
- ALDEYRA THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- ALDEYRA THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $120.75K.
- ALDEYRA THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2025 was $1.12M.
- ALDEYRA THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2024 was -$171.42K.
- ALDEYRA THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2023 was -$1.27M, a 204.11% decline from fiscal 2022.
- ALDEYRA THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2022 was $1.22M, a 99.37% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$15.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$15.23M 10-Q · filed 2026-08-06 | -$15.23M derived: sum of 3 quarters · filed 2026-08-06 | -$15.11M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $71.14K 10-Q · filed 2026-05-07 | $71.14K derived: sum of 2 quarters · filed 2026-05-07 | $191.89K derived: sum of 3 quarters · filed 2026-05-07 | $191.89K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $120.75K derived: sum of 2 quarters · filed 2026-02-27 | $120.75K derived: sum of 3 quarters · filed 2026-08-06 | $1.12M 10-K · filed 2026-02-27 |
| 2025-09-30 | $120.75K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $120.75K derived: sum of 2 quarters · filed 2026-08-06 | $1.12M 10-Q · filed 2025-11-05 | $1.13M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.00M 10-Q · filed 2026-08-06 | $1.01M derived: sum of 3 quarters · filed 2026-08-06 | $813.20K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.00M 10-Q · filed 2026-05-07 | $1.01M derived: sum of 2 quarters · filed 2026-05-07 | $813.20K derived: sum of 3 quarters · filed 2026-05-07 | $813.20K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $7.78K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$189.61K derived: sum of 2 quarters · filed 2026-02-27 | -$189.61K derived: sum of 3 quarters · filed 2026-02-27 | -$171.42K 10-K · filed 2026-02-27 |
| 2024-09-30 | -$197.39K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$197.39K derived: sum of 2 quarters · filed 2025-11-05 | -$179.20K 10-Q · filed 2025-11-05 | -$1.19M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $18.19K 10-Q · filed 2025-08-07 | -$994.12K derived: sum of 3 quarters · filed 2025-08-07 | -$1.31M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $18.19K 10-Q · filed 2025-05-14 | -$994.12K derived: sum of 2 quarters · filed 2025-05-14 | -$1.31M derived: sum of 3 quarters · filed 2025-05-14 | -$1.30M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$1.01M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$1.33M derived: sum of 2 quarters · filed 2025-02-28 | -$1.32M derived: sum of 3 quarters · filed 2025-02-28 | -$1.27M 10-K · filed 2025-02-28 |
| 2023-09-30 | -$315.76K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$310.47K derived: sum of 2 quarters · filed 2024-11-07 | -$257.91K 10-Q · filed 2024-11-07 | -$257.91K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $5.29K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $57.85K 10-Q · filed 2024-08-01 | $57.85K derived: sum of 3 quarters · filed 2024-08-01 | $1.25M derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | $52.56K 10-Q · filed 2024-05-02 | $52.56K derived: sum of 2 quarters · filed 2024-05-02 | $1.25M derived: sum of 3 quarters · filed 2024-05-02 | $1.25M derived: sum of 4 quarters · filed 2024-05-02 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $1.20M derived: sum of 2 quarters · filed 2024-03-07 | $1.20M derived: sum of 3 quarters · filed 2024-03-07 | $1.22M 10-K · filed 2024-03-07 |
| 2022-09-30 | $1.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $1.20M derived: sum of 2 quarters · filed 2023-11-03 | $1.22M 10-Q · filed 2023-11-03 | $1.22M derived: sum of 4 quarters · filed 2023-11-03 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $23.32K 10-Q · filed 2023-08-03 | $23.32K derived: sum of 3 quarters · filed 2023-08-03 | $87.10K derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $23.32K 10-Q · filed 2023-05-04 | $23.32K derived: sum of 2 quarters · filed 2023-05-04 | $87.10K derived: sum of 3 quarters · filed 2023-05-04 | $120.46M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $63.78K derived: sum of 2 quarters · filed 2023-03-09 | $120.43M derived: sum of 3 quarters · filed 2023-03-09 | $194.50M 10-K · filed 2023-03-09 |
| 2021-09-30 | $63.78K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $120.43M derived: sum of 2 quarters · filed 2022-11-10 | $194.50M 10-Q · filed 2022-11-10 | $194.50M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $120.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $194.43M 10-Q · filed 2022-08-05 | $194.43M derived: sum of 3 quarters · filed 2022-08-05 | $220.66M derived: sum of 4 quarters · filed 2022-08-05 |
| 2021-03-31 | $74.06M 10-Q · filed 2022-05-05 | $74.06M derived: sum of 2 quarters · filed 2022-05-05 | $100.29M derived: sum of 3 quarters · filed 2022-05-05 | $112.71M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $1.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $26.22M derived: sum of 2 quarters · filed 2022-03-17 | $38.65M derived: sum of 3 quarters · filed 2022-03-17 | $41.90M 10-K · filed 2022-03-17 |
| 2020-09-30 | $26.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | $38.65M derived: sum of 2 quarters · filed 2021-10-28 | $41.90M 10-Q · filed 2021-10-28 | $50.24M derived: sum of 4 quarters · filed 2021-10-28 |
| 2020-06-30 | $12.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $15.68M 10-Q · filed 2021-08-05 | $24.01M derived: sum of 3 quarters · filed 2021-08-05 | $38.86M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $3.25M 10-Q · filed 2021-05-06 | $11.59M derived: sum of 2 quarters · filed 2021-05-06 | $26.43M derived: sum of 3 quarters · filed 2021-05-06 | $26.42M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $8.33M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $23.18M derived: sum of 2 quarters · filed 2021-03-11 | $23.17M derived: sum of 3 quarters · filed 2021-03-11 | $23.58M 10-K · filed 2021-03-11 |
| 2019-09-30 | $14.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $14.84M derived: sum of 2 quarters · filed 2020-11-05 | $15.24M 10-Q · filed 2020-11-05 | $81.53M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | -$9.14K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $398.47K 10-Q · filed 2020-08-06 | $66.69M derived: sum of 3 quarters · filed 2020-08-06 | $67.80M derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | $407.61K 10-Q · filed 2020-05-07 | $66.70M derived: sum of 2 quarters · filed 2020-05-07 | $67.81M derived: sum of 3 quarters · filed 2020-05-07 | $76.84M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | $66.29M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $67.40M derived: sum of 2 quarters · filed 2020-03-12 | $76.43M derived: sum of 3 quarters · filed 2020-03-12 | $80.53M 10-K · filed 2020-03-12 |
| 2018-09-30 | $1.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $10.14M derived: sum of 2 quarters · filed 2019-11-07 | $14.24M 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $9.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $13.12M 10-Q · filed 2019-08-09 | ||
| 2018-03-31 | $4.09M 10-Q · filed 2019-05-10 | |||
| 2017-12-31 | $37.43M 10-K · filed 2019-03-08 | |||
| 2017-09-30 | $26.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | $37.38M 10-Q · filed 2018-11-14 | ||
| 2017-06-30 | $10.55M 10-Q · filed 2018-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |